BTIG Research Lowers Theravance Biopharma (NASDAQ:TBPH) Price Target to $21.00

Theravance Biopharma (NASDAQ:TBPH) had its target price reduced by equities research analysts at BTIG Research from $40.00 to $21.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. BTIG Research’s target price would suggest a potential upside of 50.11% from the company’s previous close.

A number of other analysts also recently issued reports on the stock. HC Wainwright raised their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Monday. Oppenheimer started coverage on Theravance Biopharma in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 target price for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $25.40.

Theravance Biopharma Stock Performance

Shares of TBPH stock traded down $4.96 on Tuesday, hitting $13.99. 2,578,357 shares of the stock traded hands, compared to its average volume of 498,993. Theravance Biopharma has a twelve month low of $7.90 and a twelve month high of $21.03. The firm’s 50-day moving average price is $19.35 and its two-hundred day moving average price is $16.87. The stock has a market capitalization of $708.87 million, a PE ratio of 24.59 and a beta of 0.17.

Insider Activity

In other news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the completion of the transaction, the senior vice president owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. This trade represents a 10.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Theravance Biopharma by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after acquiring an additional 54,152 shares in the last quarter. State Street Corp raised its position in Theravance Biopharma by 4.4% in the 4th quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock valued at $20,616,000 after purchasing an additional 45,987 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Theravance Biopharma by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock valued at $17,567,000 after buying an additional 40,734 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Theravance Biopharma by 12.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company’s stock valued at $16,072,000 after buying an additional 92,253 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Theravance Biopharma during the third quarter worth about $10,611,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Key Theravance Biopharma News

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company announced a deep cost reduction and restructuring expected to cut the cost base by ~60% (about $70M) and generate roughly $60–$70M of annualized cash flow, which should materially extend runway. Theravance press release
• Positive Sentiment: Balance sheet and near-term cash outlook remain supportive: $326.5M cash at Q4 2025 and roughly $400M expected at end?Q1 2026 (including milestones); management said it’s highly confident of a $100M 2026 TRELEGY milestone. Theravance press release
• Neutral Sentiment: Board has accelerated a strategic review and engaged advisors (Lazard) to evaluate alternatives — including a possible sale — which creates execution uncertainty but could unlock value if a transaction or focused restructuring materializes. Reuters: strategic review
• Negative Sentiment: Phase 3 CYPRESS missed its primary endpoint (OHSA composite) for ampreloxetine in symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy — this removes the company’s lead late?stage asset and is the proximate cause of the sharp share decline. Theravance press release
• Negative Sentiment: Market reaction: shares plunged on the trial news, trading was briefly halted, and put buying surged (roughly a ~983% jump in put volume versus typical levels), signaling elevated downside hedging/speculation and continued volatility near term.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.